Fig. 2From: Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancerFeasibility of delivering weekly paclitaxel in combination with T-DM1 with or without pertuzumab. T-DM1 trastuzumab emtansineBack to article page